Drug Shortage Report for XIGDUO
| Report ID | 72331 |
| Drug Identification Number | 02449943 |
| Brand name | XIGDUO |
| Common or Proper name | dapagliflozin and metformin hydrochloride tablets |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | METFORMIN HYDROCHLORIDE Dapagliflozin |
| Strength(s) | 1000MG 5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 6 x 10 (blister) |
| ATC code | A10BD |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2019-01-28 |
| Actual start date | |
| Estimated end date | 2019-02-04 |
| Actual end date | 2019-04-12 |
| Shortage status | Resolved |
| Updated date | 2019-04-16 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2019-01-15 | English | Compare |
| v2 | 2019-01-15 | French | Compare |
| v3 | 2019-01-29 | English | Compare |
| v4 | 2019-04-16 | English | Compare |
| v5 | 2019-04-16 | French | Compare |
Showing 1 to 5 of 5